Summary of
A New Way to Produce Hyperketonemia: Use of Ketone Ester in a Case of Alzheimer’s Disease
By
Purpose
To test whether prolonged use of a ketone monoester supplement could safely elevate plasma ketones and improve cognitive and daily function in a patient with Alzheimer’s disease.
Methods
A 63-year-old male with advanced Alzheimer’s was given oral ketone monoester (KME) over a 20-month period, while continuing his usual diet. Plasma BHB levels and cognitive/behavioral changes were monitored. Prior to KME, he had received medium-chain triglycerides (MCTs) with some improvement, but later regressed during a drug trial.
Results
KME induced plasma BHB levels of 3–7 mM, significantly higher than those achieved with MCTs. Noticeable improvements in self-care, mood, memory, and daily activities were reported within days of initiating KME and sustained throughout the treatment period. The patient regained independence in dressing, hygiene, and household tasks. Lipid markers also improved, with reductions in total and LDL cholesterol.
Conclusion
Ketone monoester safely induced robust hyperketonemia and was associated with significant functional and cognitive improvements in an Alzheimer’s patient. This suggests a promising, diet-independent strategy to overcome brain energy deficits characteristic of AD. Larger studies are needed to confirm these findings.